Abstract
AbstractPurpose Although multicentric Castleman disease is a rare but life‐threatening disease, eye complications are extremely uncommon. We present a case of refractory uveitis accompanied with Castleman disease successfully treated with tocilizmab.Methods A 58‐year‐old man with Castleman disease was introduced for refractory uveitis to Chiba University Hospital. Large cells were detected in the anterior chamber and increased vascular permeability of retinal vessels has been found in both eyes. Although the patient was treated with oral and eye drop steroid treatment, the uveitis symptoms had not decreased. The serum levels of CRP and IL‐6 were increased. The level of IL‐6 concentration in the anterior chamber was the same as the serum level of IL‐6. The humanized anti‐IL‐6 receptor‐antibody (tocilizumab: 8 mg/kg per two weeks) was administrated for the patient because of poor general condition. The effect of tocilizumab was evaluated with routine ophthalmological examinations, fluorescein angiography (FA), Glodmann perimetry, and OCT.Results After tocilizmab treatment, large cells in the anterior chamber were undetectable and vascular permeability was improved in FA. The serum levels of CRP and IL‐6 decreased and the general condition improved. The side effect of tocilizumab was not observed during the treatment.Conclusion Tocilizumab treatment was significantly effective for uveitis accompanied with Castleman disease. Although it is extremely rare, uveitis accompanied with Castleman disease may reflect poor general condition in patients with Castleman disease, and it may be one of the hallmarks to consider tocilizumab treatment.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
